10+ weeks
At BGI there aim is to apply their high genetic research capacity and well-developed global network to solving current health issues worldwide. They are committed to raising genetic health awareness and reducing the rate of major disease by offering a broad array of accurate, reliable and affordable genetic tests and molecular diagnostics services.
As a market leader in non-invasive prenatal test (NIPT), the NIFTY™ test, is offered by over 2000 partners in more than 50 countries across the world. As of August 2014, they had processed over 350,000 test samples, making NIFTY™ the world’s most trusted NIPT screen.
They have a product portfolio which also includes the below test families:
- Vista™ – carrier screening tests
- Nova™ – newborn screening tests
- Sentis™ – screening tests and targeted treatment tests for cancer
To find out more information visit www.bgi-international.com.
BGI, founded in 1999 with the vision of using genomics to benefit the human race, is now the world’s largest genomics organisation.
BGI includes both private non-profit research institutes and sequencing application commercial units. Together with its affiliated offshoots, BGI Americas and BGI Europe, BGI has established partnerships and collaborations with leading academic and government research institutions as well as global biotechnology and pharmaceutical companies, to support a variety of healthcare, agricultural, environmental and related applications.
Through a combination of high-throughput, cost-effective genomics platforms, its large sample collection and storage capability, in-depth bioinformatics analysis and a core commitment to education, BGI is dedicated to ensuring that omics science and technology can be made to work for the benefit of everyone.
Click here to visit: NIFTY™ test for Patients
| TEST | Simply NIFTY™ | NIFTY™ |
|---|---|---|
| Company website | http://www.niftytest.com/ | http://www.niftytest.com/ |
| COMPANY | BGI Diagnostics | BGI Diagnostics |
| Test Origin | China | China |
| Laboratory Location | Hong Kong | Hong Kong |
| Type of cfDNA analysis | Massively parallel genomic sequencing | Massively parallel genomic sequencing |
| Screen Population | GENERAL & HIGH RISK | GENERAL & HIGH RISK |
| Number of tests performed | 1 Million | 1 Million |
| Clinical data number re test performance | >112,000 | >112,000 |
| About the test | About the test | |
| Gestational age | 10+ weeks | 10+ weeks |
| Pregnancies Screened | Pregnancies Screened | |
| Singletons | Singletons | |
| Naturally conceived | YES | YES |
| IVF (Self) | YES | YES |
| IVF (Donor) | YES | YES |
| Multiples (Twins) | Multiples (Twins) | |
| Naturally conceived | YES | YES |
| IVF (Self) | YES | YES |
| IVF (Donor) | YES | YES |
| Risk analysis | All give individualized risk score plus high / low result for each patient | All give individualized risk score plus high / low result for each patient |
| Fetal fraction redraw level | 3.5% | 3.5% |
| Fetal fraction quoted | Yes | Yes |
| Redraw rate | <3% | <3% |
| Chance of result after 2nd blood sample | 99% | 99% |
| Chromosomes analysis | Current Validated Detection Rates 01/06/2015 | Current Validated Detection Rates 01/06/2015 |
| Combined false positive rate T12/T18/T13 | 0.1% | 0.1% |
| T21 Down’s syndrome | >99% | >99% |
| T18 Edwards’ syndrome | >98% | >98% |
| T13 Patau’s syndrome | >99% | >99% |
| Triploidy | n/a | n/a |
| Fetal sex / presence of Y chromosome: accuracy | YES: 98% | YES: 98% |
| Sex Aneuploid Conditions | Y aneuploidy (optional no extra charge) | Y aneuploidy (optional no extra charge) |
| X0 (Turner syndrome) | NO | YES (Singleton only) |
| XXX (Triple X) | NO | YES (Singleton only) |
| XYY (Jacob’s syndrome) | NO | YES (Singleton only) |
| XXY (Klinefelter syndrome) | NO | YES (Singleton only) |
| Micro deletions (Optional) | NO | YES (+ £100) |
| Turnaround Time (TAT) working days | 7 | 7 |